Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
A primary goal of this clinical research study is to find the highest safe dose of sorafenib
that can be given in combination with idarubicin and Ara-C for the treatment of acute
myelogenous leukemia (AML) and high-risk, myelodysplastic syndrome (MDS).
Once the highest safe dose is found, researchers will then try to learn if this combination
treatment can help control AML and high-risk MDS in newly diagnosed patients. The safety of
this treatment combination will also be studied.